PDL BioPharma Operating Income 2006-2020 | PDLI

PDL BioPharma operating income from 2006 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
PDL BioPharma Annual Operating Income
(Millions of US $)
2020 $
2019 $-100
2018 $-51
2017 $194
2016 $129
2015 $550
2014 $546
2013 $427
2012 $355
2011 $344
2010 $211
2009 $297
2008 $243
2007 $184
2006 $155
2005 $-49
PDL BioPharma Quarterly Operating Income
(Millions of US $)
2020-12-31
2020-06-30 $-14
2020-03-31 $-32
2019-12-31 $-92
2019-09-30 $9
2019-06-30 $-9
2019-03-31 $-8
2018-12-31 $33
2018-09-30 $37
2018-06-30 $-125
2018-03-31 $4
2017-12-31 $30
2017-09-30 $33
2017-06-30 $113
2017-03-31 $19
2016-12-31 $-8
2016-09-30 $33
2016-06-30 $11
2016-03-31 $93
2015-12-31 $162
2015-09-30 $116
2015-06-30 $131
2015-03-31 $142
2014-12-31 $99
2014-09-30 $159
2014-06-30 $156
2014-03-31 $132
2013-12-31 $108
2013-09-30 $92
2013-06-30 $142
2013-03-31 $85
2012-12-31 $85
2012-09-30 $80
2012-06-30 $121
2012-03-31 $70
2011-12-31 $68
2011-09-30 $80
2011-06-30 $118
2011-03-31 $78
2010-12-31 $-28
2010-09-30 $75
2010-06-30 $112
2010-03-31 $53
2009-12-31 $53
2009-09-30 $66
2009-06-30 $120
2009-03-31 $58
2008-12-31 $53
2008-09-30 $57
2008-06-30 $96
2008-03-31 $37
2007-12-31 $-25
2007-09-30 $-8
2007-06-30 $10
2007-03-31 $-1
2006-12-31 $-4
2006-09-30 $-8
2006-06-30 $-8
2006-03-31 $-27
2005-12-31 $-35
2005-09-30 $-43
2005-06-30 $-3
2005-03-31 $-85
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71